SMT201500056B - Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancro - Google Patents

Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancro

Info

Publication number
SMT201500056B
SMT201500056B SM201500056T SM201500056T SMT201500056B SM T201500056 B SMT201500056 B SM T201500056B SM 201500056 T SM201500056 T SM 201500056T SM 201500056 T SM201500056 T SM 201500056T SM T201500056 B SMT201500056 B SM T201500056B
Authority
SM
San Marino
Prior art keywords
methylaminophenoxy
pyridin
cancer treatment
benzamide derivatives
benzamide
Prior art date
Application number
SM201500056T
Other languages
English (en)
Italian (it)
Inventor
Yutaka Kojima
Takumi Sumida
Makoto Sakamoto
Kazuya Yamaguchi
Yuki Terauchi
Masamichi Shirakura
Yasuo Harada
Takashi Makagawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SMT201500056B publication Critical patent/SMT201500056B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
SM201500056T 2010-10-04 2015-03-09 Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancro SMT201500056B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38939310P 2010-10-04 2010-10-04
PCT/JP2011/073165 WO2012046825A1 (en) 2010-10-04 2011-10-03 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer

Publications (1)

Publication Number Publication Date
SMT201500056B true SMT201500056B (it) 2015-05-05

Family

ID=44872549

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500056T SMT201500056B (it) 2010-10-04 2015-03-09 Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancro

Country Status (29)

Country Link
US (7) US8946437B2 (ru)
EP (1) EP2624833B1 (ru)
JP (1) JP5715690B2 (ru)
KR (1) KR101797797B1 (ru)
CN (1) CN103189061B (ru)
AR (1) AR083287A1 (ru)
AU (1) AU2011313236B2 (ru)
BR (1) BR112013007841B1 (ru)
CA (1) CA2813153C (ru)
CO (1) CO6660459A2 (ru)
DK (1) DK2624833T3 (ru)
EA (1) EA021627B1 (ru)
ES (1) ES2526574T3 (ru)
HK (1) HK1187540A1 (ru)
HR (1) HRP20141237T1 (ru)
IL (1) IL225520A (ru)
MX (1) MX2013003589A (ru)
MY (1) MY157563A (ru)
NZ (1) NZ609151A (ru)
PL (1) PL2624833T3 (ru)
PT (1) PT2624833E (ru)
RS (1) RS53749B1 (ru)
SG (1) SG189146A1 (ru)
SI (1) SI2624833T1 (ru)
SM (1) SMT201500056B (ru)
TW (1) TWI526431B (ru)
UA (1) UA110037C2 (ru)
WO (1) WO2012046825A1 (ru)
ZA (1) ZA201302332B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101797797B1 (ko) * 2010-10-04 2017-11-14 오쓰까 세이야꾸 가부시키가이샤 암치료를 위한 4-(메틸아미노페녹시)피리딘-3-일-벤즈아미드 유도체
JP6066806B2 (ja) * 2012-04-03 2017-01-25 大塚製薬株式会社 医薬
AU2020244921A1 (en) * 2019-03-25 2021-09-02 Otsuka Pharmaceutical Co., Ltd. Antitumor composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
KR100927563B1 (ko) 2004-08-06 2009-11-23 오쓰까 세이야꾸 가부시키가이샤 방향족 화합물
RU2444362C2 (ru) 2005-12-05 2012-03-10 Оцука Фармасьютикал Ко., Лтд. Лекарственное средство
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
KR101797797B1 (ko) * 2010-10-04 2017-11-14 오쓰까 세이야꾸 가부시키가이샤 암치료를 위한 4-(메틸아미노페녹시)피리딘-3-일-벤즈아미드 유도체
AU2020244921A1 (en) * 2019-03-25 2021-09-02 Otsuka Pharmaceutical Co., Ltd. Antitumor composition

Also Published As

Publication number Publication date
SI2624833T1 (sl) 2015-03-31
TWI526431B (zh) 2016-03-21
BR112013007841B1 (pt) 2020-03-03
US20170298023A1 (en) 2017-10-19
CA2813153A1 (en) 2012-04-12
ZA201302332B (en) 2014-07-30
EP2624833B1 (en) 2014-12-10
CA2813153C (en) 2019-01-15
RS53749B1 (en) 2015-06-30
HRP20141237T1 (hr) 2015-02-13
NZ609151A (en) 2015-01-30
US20130267565A1 (en) 2013-10-10
UA110037C2 (ru) 2015-11-10
PT2624833E (pt) 2014-12-26
JP5715690B2 (ja) 2015-05-13
EA021627B1 (ru) 2015-07-30
KR101797797B1 (ko) 2017-11-14
US20210017134A1 (en) 2021-01-21
MX2013003589A (es) 2013-06-24
EP2624833A1 (en) 2013-08-14
US20200031773A1 (en) 2020-01-30
ES2526574T3 (es) 2015-01-13
TW201307289A (zh) 2013-02-16
CN103189061B (zh) 2015-09-02
KR20130121826A (ko) 2013-11-06
MY157563A (en) 2016-06-30
JP2013538785A (ja) 2013-10-17
BR112013007841A2 (pt) 2016-06-07
DK2624833T3 (en) 2015-01-05
US20230139808A1 (en) 2023-05-04
US20150105432A1 (en) 2015-04-16
SG189146A1 (en) 2013-05-31
WO2012046825A1 (en) 2012-04-12
HK1187540A1 (en) 2014-04-11
US8946437B2 (en) 2015-02-03
IL225520A0 (en) 2013-06-27
US20180265471A1 (en) 2018-09-20
IL225520A (en) 2016-05-31
EA201390323A1 (ru) 2013-09-30
CO6660459A2 (es) 2013-04-30
AR083287A1 (es) 2013-02-13
AU2011313236A1 (en) 2013-04-18
AU2011313236B2 (en) 2016-05-19
PL2624833T3 (pl) 2015-05-29
CN103189061A (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
SMT201500168B (it) Derivati di piperidinone come inibitori di mdm2 per il trattamento del cancro
SMT201700053B (it) Derivato del cicloalcano
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
SMT201700003B (it) Didropiridoni come inibitori del fattore xia
SMT201500270B (it) Derivati di pirrolotriazinone come inibitori di pi3k
SMT201600298B (it) Derivati n3-sostituiti-n1-solfonil-5- fluoropirimidinone
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
BR112014007603A2 (pt) métodos de tratamento do câncer
FI20125146A (fi) Selluloosamassan esikäsittelymenetelmä
DK2707030T3 (da) Cancerbehandlinger
DK3702374T3 (da) Fremsgangsmåde til fremstilling for cyclodextrin-derivater
BR112014012880A2 (pt) tratamento imunogênico do câncer
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
SMT201600235B (it) Predittori per il trattamento del cancro
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
HK1212617A1 (zh) 白癜風的治療
BR112013011659A2 (pt) métodos de tratamento do câncer
DK2944327T3 (da) Ultraviolet sterilisator
SMT201400080B (it) Derivati di pirazinoossazepina
SMT201600405B (it) Derivati di arilalchilamminocarbossammide fluorurati
SMT201600296B (it) Lapatinib per il trattamento del cancro
FI20135757A (fi) Säädettävä kenkäteline
DK2892535T3 (da) Fremgangsmåde til adjuverende cancerbehandling